At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE